Clinical Trial

Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind Study

Name: Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind Study — clinical trial record (NCT07440537)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the efficacy and safety of ICP-488 in subjects with cutaneous lupus erythematosus (CLE).

Protocol Amendment History 1 change

critical Recruitment opened 2026-06-09

Trial Details

NCT Number	NCT07440537
Lead Sponsor	Beijing InnoCare Pharma Tech Co., Ltd.
Conditions	Cutaneous Lupus Erythematosus (CLE)
Enrollment	105 participants
Start Date	2026-04-27
Primary Completion	2027-03 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2026-06-08